跳至主要内容
临床试验/NCT04641000
NCT04641000终止不适用

The Alberta BLOOM Long Term Follow Up Study: The Microbiome of Preterm Children in Immune Development

University of Calgary1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2020年11月20日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
15
试验地点
1
主要终点
Allergies

研究概览

简要总结

This is a prospective, observational clinical cohort study involving children born very preterm at less than 31 weeks and six days gestation. The purpose of this study is to investigate the microbiome (the collection of microbes in a biological site) alternations resulting from preterm birth and associations with the risk of immune dysregulation, asthma and allergies.

详细描述

One important factor in gut health is the large community of microbes (tiny living things such as bacteria) that live on the human body called the microbiome. Recent studies have shown that premature babies are more likely to have changes in their gut microbiome that are associated with health issues. However, the specific microbiome features that are involved in the development of premature babies is still unknown. Therefore, this study examines the impact of very premature birth on the baby's microbiome, and how microbiome alterations are involved in health issues such as immune dysregulation, allergies and asthma.

The large communities of microbes in the gut play a major role on the microbiome that will form during infancy and childhood. Factors such as diet, exposure to antibiotics, surgical procedures, and mode of delivery, can strongly affect the dynamics microbiome development. It is well known that microbiome alterations are associated with disorders such as asthma. However, the features involved in disease development and progression are highly understudied. Through this clinical study, we will evaluate associations between the early patterns of microbial colonization in premature infants and their risk to develop asthma later in childhood.

The hypothesis of the study is that microbial alterations resulting from preterm birth causally contribute to the allergy and asthma risk in infants (defined by atopic-wheeze) through immune mechanisms.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
1 Year 至 2 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Born at ≤ 31 weeks + 6 days gestation (316/7 weeks);
  • Previously participated in the PROBIO and/or BLOOM PTN and/or BLOOM PTB research studies.
  • Provide a signed and dated informed consent form.
  • Willing and able to attend a clinic visit at Alberta Children's Hospital in Calgary, Alberta.
  • Parent/guardian providing consent must be able to speak and understand English.

排除标准

  • Has congenital gastrointestinal anomalies or has a history of gastrointestinal surgery.
  • Has major chromosomal anomalies.

结局指标

主要结局

Allergies

时间窗: 1-2 Years Corrected Gestational Age

Skin reactivity to common allergens as assessed by a skin prick test.

Asthma Risk

时间窗: 1-2 Years Corrected Gestational Age

Health outcomes such as asthma risk that are influenced by novel linkages between gut microbiome features (taxonomical and functional) as assessed by the Asthma Predictive Index, which involves determining history of wheeze, atopic dermatitis, familial history and eosinophilia.

Microbiome Establishment and Assembly

时间窗: 1-2 Years Corrected Gestational Age

Fecal microbial diversity and the relative abundance of bacterial and eukaryotic taxa, as assessed by polymerase chain reaction of the 16S and ITS2 gene and functional analysis on 16S taxonomic surveys for all participants from birth to around 1-year CGA. Changes in fecal microbial diversity and microbial population structures from birth to around 1-year CGA for all participants as assessed by shotgun metagenomics.

Metabolome

时间窗: 1-2 Years Corrected Gestational Age

Human and microbial metabolites as assessed by untargeted metabolomics, ultra-performance liquid chromatography ultrahigh-resolution Fourier transform (FT) combined with mass spectrometry to identify human and microbial metabolites for all participants from birth to around 1-year CGA.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Marie-Claire Arrieta

Dr.

University of Calgary

研究点 (1)

Loading locations...

相似试验

The Alberta BLOOM Long Term Follow Up Study | 临床试验